Cell Therapeutics Rises 40% (CTIC)
Cell Therapeutics (NASDAQ: CTIC) rose 40% on Friday to $0.30. A press release came out this morning announcing that the FDA had provided guidance for a new clinical trial for the company's drug, pixantrone for the treatment of diffuse large B-cell lymphoma ("DLBCL").
"The new clinical trial, referred to as the PIX-R or PIX 306 trial, will compare a combination of pixantrone plus rituximab to a combination of gemcitabine plus rituximab in patients with relapsed or refractory DLBCL who have received one to three prior lines of therapy, utilizing progression free survival ("PFS") and Overall Survival ("OS")as co-primary endpoints of the study."
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.